CorMedix (CRMD) Net Equity Issued and Repurchased (2015 - 2025)

CorMedix (CRMD) has 11 years of Net Equity Issued and Repurchased data on file, last reported at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Net Equity Issued and Repurchased fell 81.36% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $7.8 million (down 57.46% YoY), and the FY2025 full-year result was $7.8 million, down 58.75% from the prior year.
• Net Equity Issued and Repurchased eased to $1.0 million in Q4 2025, from $6.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $41.5 million in Q1 2021 to a low of $300000.0 in Q3 2022.
• A 5-year average of $8.2 million and a median of $5.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 1578.41% in 2021 and sank 92.82% in 2023, its largest moves.
• Tracing CRMD's Net Equity Issued and Repurchased over 5 years: stood at $41.5 million in 2021, then slumped by 85.42% to $6.0 million in 2022, then slumped by 92.82% to $433901.0 in 2023, then jumped by 1168.93% to $5.5 million in 2024, then plunged by 81.36% to $1.0 million in 2025.
• Business Quant data shows CRMD's Net Equity Issued and Repurchased at $1.0 million in Q4 2025, $6.8 million in Q1 2025, and $5.5 million in Q4 2024.